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Almost 25 years ago, the concept of the ‘mosaic of autoimmunity’ was introduced to the scientific community, and
since then this concept has continuously evolved, with new pebbles being added regularly. We are now looking at
an era in which the players of autoimmunity have changed names and roles. In this issue of BMC Medicine, several
aspects of autoimmunity have been addressed, suggesting that we are now at the forefront of autoimmunity
science. Within the environmental factors generating autoimmunity are now included unsuspected molecules such
as vitamin D and aluminum. Some adjuvants such as aluminum are recognized as causal factors in the
development of the autoimmune response. An entirely new syndrome, the autoimmune/inflammatory syndrome
induced by adjuvants (ASIA), has been recently described. This is the new wind blowing within the branches of
autoimmunity, adding knowledge to physicians for helping patients with autoimmune disease.
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Almost 25 years ago the concept of the ‘mosaic of auto-
immunity’ [1] was introduced to the scientific community.
Since then, it has continuously evolved, with new tiles
being added regularly [2], and we are now looking at an
era in which the players of autoimmunity have changed
names and roles. In this issue of BMC Medicine, several
aspects of autoimmunity have been addressed suggesting
that we are now at the forefront of autoimmunity science.
One of the mainstays of the mosaic concept is that auto-
immune diseases (ADs) occur in genetically predisposed
individuals [3]. This concept has now been expanded by
recent evidence of ‘familial autoimmunity’: not only is
there familial aggregation for individual ADs [4,5], but
there is also a familial aggregation of diverse autoimmune
diseases. This was brought to light by evidence from a sys-
tematic review and meta-analysis performed by Cárdenas-
Roldán et al. [6]. Physicians should be aware that familial
autoimmunity is a common finding, especially for some
specific disorders, such as autoimmune thyroid disease and
systemic lupus erythematosus (SLE), suggesting a stronger
shared genetic influence in their development.* Correspondence: shoenfel@post.tau.ac.il
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reproduction in any medium, provided the orStrengthening the theory of a genetic basis is the evi-
dence that ADs occur more often in young people [7].
However, although ADs were thought to be rare in older
people, the validity of this assumption has been challenged,
and a tendency towards more severe autoimmunity in
older people has been noted [8]. A possible explanation for
this paradox comes from another characteristic of the
disease mosaic, namely, the presence of an abnormal im-
mune response. Vadasz et al. [9] suggested that expansion
of many protective regulatory mechanisms and especially
of peripheral CD4+CD25highFoxP3+ T-regulatory cells, is
very characteristic in elderly people. It is possible that
during aging, an imbalance between thymic and peripheral
regulatory T-cell output occurs, with the ratio favoring
the peripheral component, which possibly allows a pro-
inflammatory response and increases the susceptibility to
autoimmunity. Furthermore, in addition to this disruption
of adaptive immunity, it has been shown that disruption
of the autoimmune response also occurs in the innate
immune system [10]. Pollard et al. [11] suggested that dif-
ferences in autoimmune responses are mainly mediated by
the dichotomy in Toll-like receptor (TLR) signaling that
distinguishes interferon regulatory factor 7-mediated type I
interferon production from nuclear factor-kappa B (NFκB)-
driven pro-inflammatory cytokine expression. Indeed, TLRs
play a crucial role in the activation of both innate and adap-
tive immunity [12]. By recruiting various protein kinasesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to the activation of NFκB [12]. By contrast, self-reactive
antibodies against self-reactive or cross-reactive DNA co-
engage antigen receptors and TLRs, leading to a continuous
activation of these auto-reactive B cells and the develop-
ment of autoimmune disease [12].
Nonetheless, environmental factors are still central to
autoimmunity [13]. Indeed, it is possible that the discre-
pancies in the immune system may lead to infections
(which are indeed more frequent in elderly people) thus
triggering ADs [14]. Thus, on the one hand, a huge num-
ber of microorganisms have been identified as associated
with the onset of an overt immune-mediated disease, and
on the other hand, patients with ADs are at a major risk
for infections [15].
Ramagopalan et al. [16] analyzed hospital admissions
and death certificates across England, and found that
the risk of tuberculosis (TB) is significantly increased in
patients with immune-mediated diseases, highlighting the
need for TB screening control and treatment policies in
these patients. It would be interesting to confirm whether
TB is a consequence of the immune system imbalance of
the disease per se, or a result of the background therapy,
or if it represents another causative factor of ADs [17].
It has been shown that a link exists between the myco-
bacterium, ADs, and, surprisingly, another component of
the puzzle, namely, vitamin D [18]. Vitamin D plays a key
role as an immunomodulator in autoimmunity [19,20].
This role of vitamin D seems to be so important that ADs
show seasonality (due to different levels of UV exposure),
and even the month of birth may influence the risk of
onset of an AD, as shown by Disanto et al. [21]. Moreover,
Tincani et al. [22], in their review, emphasized that pa-
tients affected with Sjögren's syndrome (SS) who have low
levels of vitamin D are at a higher risk of developing
severe complications such as lymphoma and peripheral
neuropathy [23,24]. The need to provide vitamin D sup-
plementation for patients with autoimmune diseases, in-
cluding SS, is clear. Moreover, the cost–benefit ratio of
providing vitamin D as a preventative medicine to the
general population should be evaluated, together with the
routine monitoring of gestational vitamin D levels [20].
Finally, because (no-longer-just-a-)vitamin D has several
physiological properties involved with the innate immune
defense against TB, the role of this vitamin in the treat-
ment of TB should be evaluated, especially when asso-
ciated with autoimmunity [18].
Thus, it is evident that every day, people are exposed
to several triggering factors for ADs. People can be ex-
posed to such elements through diet (for example, vitamin
D), and other sources. For instance, another defendant,
aluminum (alum), is used as an adjuvant in vaccines, and
its association with autoimmunity has recently been
highlighted [25]. Alum can be viewed as a nanomaterial,that is, a nanocrystalline compound spontaneously forming
micron/submicron-sized agglomerates.
Alum has a number of mechanisms by which it works
as an adjuvant (Table 1). Moreover, it can be detected
within monocyte-lineage cells long after immunization in
presumably susceptible individuals who develop systemic/
neurologic symptoms. Khan et al. [26] showed that in
mice, intramuscular injection of alum-containing vaccines
was associated with appearance of aluminum deposits in
distant organs such as the spleen and brain, where they
were still detected 1 year after injection. The chemokine
CCL-2 seems to be implicated in systemic diffusion of
aluminum particles captured by monocyte-lineage cells,
and in the subsequent neurodelivery of these particles.
These various lines of evidence reinforce the idea that
alum is neurotoxic, and that continuously escalating
doses of this poorly biodegradable adjuvant in the popu-
lation may become insidiously unsafe, especially in cases
of over-immunization or immature/altered blood–brain
barrier or high constitutive CCL-2 production.
It is possible that this is part of the explanation for the
real new wave in autoimmunity, that of autoimmune/
inflammatory syndrome induced by adjuvants (ASIA)
[27]. This syndrome comprises four conditions, namely
siliconosis, Gulf War syndrome, macrophagic myofasciitis
syndrome, and post-vaccination phenomena, which have
in common a history of previous exposure to an adjuvant
and a group of similar clinical features. Consequently, the
importance of discovering a pathogenic role for alum
must be emphasized. This compound has been considered
a safe adjuvant for 90 years. However, it is now known to
be an inducer of dendritic cells and complement activa-
tion, which is capable of increasing the levels of chemo-
kine secretion at the injection site and of enhancing the
secretion of key T-helper (Th)1 and Th17-cell polarizing
cytokines such as interleukin-12 [28]. All these effects lead
to development of an autoimmune response. Because
many of the symptoms of ASIA could be neurologically
dependent, the possibility that alum might traffic to the
brain raises questions about its relevance to autoimmune
disease. Indeed, the central nervous system (CNS) is still
attracting most of the interest of autoimmune scientists,
especially with regard to SLE, the disease considered the
forerunner of ADs [29].
Neuropsychiatric (NP)SLE is triggered by multiple me-
chanisms, including several autoantibodies. One of the
leading pathogenic autoantibodies in NPSLE is anti-
ribosomal P protein. Carmona-Fernandes et al. [30] found
that the specificity, sensitivity, positive predictive value,
and negative predictive value of anti-Rib-P for SLE diag-
nosis were 99.4%, 14.2%, 90%, and 76.4%, respectively.
Although, anti-Rib-P was not clearly associated with any
clinical condition, including NPSLE, in that study, none-
theless, the effects of these autoantibodies on the CNS
Table 1 Specific mechanisms relating to the adjuvant properties of aluminum compounds [28]
Mechanism Characteristics
Depot effect Alum-induced consolidation of the desired antigen at the injection site results in slow
release of the antigen to antigen-presenting cells for an extended period of time
Activation of DCs by lipid sorting Aluminum salts induce activation of DCs and complement components, and increase
the level of chemokine secretion in the injection site. Aluminum-based salts firmly
bind to and alter the structure of lipids in the plasma membrane of DCs
NLRP3 inflammasome-independent DC activation Membrane proximal events unrelated to the NLRP3 inflammasome are sufficient to
mediate DC activation in response to alum
Augmentation of adjuvant properties of alum by uric acid Increase in uric acid mediates upregulation of MHC class II in monocytes via an IL-4
dependent mechanism
Host cell DNA The host cell DNA can enhance the adjuvant properties of alum
Alum-dependent increase in IgE levels Promotes allergy
Amyloid plaque formation Alum promotes the formation of amyloid plaques by catalyzingpolymerization of β-
amyloid
Increased Tau protein Alum may increase the levels of Tau protein
Abbreviations: DC, dendritic cell; IL, interleukin; MHC, major histocompatibility complex; NLRP3, nucleotide-binding oligomerization domain-like receptor family,
pyrin domain-containing 3.
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most interesting investigations showed that intracerebro-
ventricular injection of an anti-DNA antibody carrying the
16/6 idiotype, which induces the production of anti-Rib-P
antibodies, provoked deficiencies in olfactory capabilities
and depression in mice [31,32]. Likewise, the 16/16 anti-
body bound to similar areas in the olfactory machinery as
those to which anti-P ribosomal antibodies bind. Kivity
et al. [33] identified another weapon at the armory of the
16/6 idiotype-expressing antibodies, showing that these
antibodies can induce brain inflammation and cognitive
impairment in mice. These reports on the effect of this
idiotype of the human anti-DNA antibody shed further
light on the diverse mosaic pathophysiology of neuro-
psychiatric lupus, and indicate that there is a possibility of
molecularly targeting the disease [34]. This potential for
treatment of SLE was addressed by Gono and coworkers
[35], who highlighted the possibility that the differences in
the cross-reactivity of each autoantibody with the nervous
system might explain the diverse clinical features in
NPSLE, and that the identification of autoantibody targets
could lead to the development of novel therapies; for in-
stance, by protecting specific neuronal cells.
One of the autoimmune conditions more clearly associ-
ated with CNS involvement is anti-phospholipid syn-
drome (APS). Katzav et al. [36] have shown that this AD,
besides being characterized by the presence of autoanti-
bodies, can be triggered experimentally by coagulopathy.
Indeed, this group found that both heterozygous and
homozygous Factor V Leiden (FVL) transgenic mice that
were immunized with β2-glycoprotein I had significantly
higher and longer-lasting immune responses. Further-
more, because these responses were dependent on the
FVL mutation allele load, the research suggests thatgenetically mediated coagulopathies increase the risk of
developing coagulation-targeted autoimmune responses.
Moreover, raised levels of circulating anti-phospholipid
antibodies seem to lead inevitably to neurodegeneration.
The thrombophilic network is also involved in another
autoimmune disorder, celiac disease. Lerner et al. [37]
showed that in addition to the well-known thrombogenic
factors, the presence of anti-phospholipid antibodies,
namely anti-phosphatidylserine/prothrombin and anti-
prothrombin, might play a pathogenic role by increasing
the risk of intestinal injury, endothelial dysfunction, plate-
let abnormality, and enhanced apoptosis. Studies are ur-
gently awaited to address the potential of treating patients
with ADs by targeting these antibodies.
A further component in the mosaic of autoimmunity is
the question of what stays in the renal pyramids. Renal
involvement represents a major issue in autoimmune
connective tissue diseases (CTDs). The main question is
whether renal damage is caused by the underlying disease
or by interventions, particularly by drug reactions as
described by Kronbichler and Mayer [38]. Consequently,
physicians should always take kidney function into account
when treating CTDs [39]. Nonetheless, recent evidence
suggests that the real hub for presenting T cells is in the
lung [40]. Indeed, T-cell blasts do not enter the CNS
efficiently, and they gain this capacity only after residing
transiently within the lung tissues. In these tissues, the T
cells are stimulated, after which they proliferate strongly,
acquire migratory properties by rearranging specific genes
and producing targeting chemokines, and can then enter
the circulation and induce CNS disease. There are several
implications for such phenomena. For instance, the role of
smoke as a risk factor in ADs becomes even more import-
ant when we consider the exposure of disease-inducing
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ond, the development of drugs based on the concept of
arresting T cells at a hub (that is, in the lung), is a potential
therapy and should be encouraged [41].
Phosphodiesterase-targeted therapies 4 are also a prom-
ising tool for treating patients with a variety of auto-
immune diseases. Intriguingly, these inhibitors have been
used to treat both diseases of the CNS (such as Parkinson’s
disease) and of the lung (such as chronic obstructive pul-
monary disease), suggesting a common soil between the
lung and the CNS.
Finally, the revolutionary roads traced by biologic ther-
apies continue to provide benefits for patients with ADs.
Rosman et al. [42], in their review of the advantages and
drawbacks of biologic therapies for autoimmune disease,
focused on the importance of having a range of drugs
available to treat patients with severe or resistant dis-
ease. The important issue here is having a range of dif-
ferent targets, allow personalization of therapy not only
for the individual, but also on the basis of the pathogenic
mechanisms underlying each specific disorder.
Conclusion
In conclusion, a new wind is blowing within the branches
of autoimmunity, from the unexplored continent of ASIA
syndrome [27], which is reaching the arduous banks
of personalized medicine and bringing new hope to the
leaves of autoimmunity.
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